Poland is a country with a relatively low incidence and high mortality rate of malignant tumors, where too much money is spent on hospitalization and too little on systemic therapies or radiotherapy - such as: The conclusions are contained in a report prepared by the Institute of Health Protection.
The study "Fighting cancer and oncological care in Poland in the face of demographic and epidemiological challenges - proposed solutions" was presented on April 8 this year. during a meeting of the Parliamentary Team for Oncology, in which Deputy Minister of Health Beata Małecka-Libera also participated.
According to the analyzes of the National Cancer Registry, in 2011, over 144 people were diagnosed with cancer in Poland. people, and forecasts assume that in the next decade this number will increase to approximately 185 thousand. each year. While the incidence in our country is relatively low compared to the European Union, the mortality rate is high. The effectiveness of the treatment is simply worse. According to the authors of the report, this is the result of, among others, different distribution of expenditure on individual levels of treatment. For example, in Sweden or Denmark, where the effectiveness of treatment is higher, it is based on specialists working in outpatient treatment and hospitals. They have easy and quick access to necessary diagnostics, treatment in highly specialized hospitals, and modern radiotherapy therapies. The vast majority (up to 80-90%) of radiotherapy procedures are performed on an outpatient basis. This is possible thanks to a denser network of radiotherapy centers, specially dedicated transport or the so-called hotel hospitalizations, i.e. patients staying outside the oncology hospital. Meanwhile, in our country, the largest part (77%) of the total costs of cancer treatment in 2009-2013 was hospital treatment. In many countries with better treatment results than ours, the principle "those who do not have to, should not stay in hospital" also apply in oncology.
According to the authors of the report, the relocation of funds within oncology is realistic, and patients will benefit from it. The presented forecast assumes that in the next decade it will be possible to relocate at least PLN 1,5 billion, and within 21 years - almost PLN 5 billion. If we divide these funds in equal proportions between chemotherapy, teleradiotherapy and surgical oncology procedures, then - according to experts' calculations - it would be possible to additionally finance a gradually increasing number of chemotherapy and teleradiotherapy procedures (up to approximately 10) and oncological surgical procedures throughout the year ( up to approx. 20 thousand).
The full report can be found here.